Can I legally buy sincalide in the EU if I have a doctor's prescription?

No. Sincalide lacks EMA authorisation, so it cannot be legally supplied or dispensed in any EU member state, regardless of a prescription or medical justification. Your doctor would need to prescribe an approved alternative diagnostic method instead, such as ultrasound or MRI-based imaging.

Is sincalide ever used in EU hospitals for compassionate reasons?

Extremely rarely, and only through complex unlicensed-medicine licensing procedures managed by national regulators. Since non-pharmacological diagnostic alternatives are readily available (ultrasound, MRCP), compassionate-use approval for sincalide is highly unlikely to be granted in practice.

Could sincalide ever be approved in the EU in the future?

Theoretically yes, but commercially unlikely. A pharmaceutical company would need to submit a new Marketing Authorisation Application to the EMA and invest in modern regulatory data packages. No company has signalled intent to do so, and diagnostic imaging alternatives reduce the commercial incentive.

Why is sincalide approved in the US but not the EU?

Sincalide was approved by the FDA in 1982, before the EMA centralised procedure became standard. Companies pursuing approval at that time could focus on profitable markets. The cost and complexity of seeking EU approval for an older, niche diagnostic compound likely made the investment unattractive.

What diagnostic alternatives are available in the EU if sincalide cannot be used?

EU radiologists primarily use ultrasound, CT imaging, and magnetic resonance cholangiopancreatography (MRCP) to assess gallbladder and biliary function. These methods are widely available, safe, and clinically effective, and they do not require pharmacological stimulation.

Sincalide Legal Status in the EU: Regulatory Guide

Sincalide is an FDA-approved synthetic peptide used to stimulate gallbladder contraction during diagnostic imaging procedures. However, sincalide is **not authorised by the European Medicines Agency (EMA)** and therefore not legally marketed as a pharmaceutical product in EU member states. While it is approved and available in the United States and Canada, European patients and healthcare providers should be aware that sincalide lacks formal EU regulatory approval, which affects its legal availability, reimbursement status, and clinical use across the bloc. This guide explains sincalide's regulatory standing in Europe and what that means in practice.

Sincalide's Regulatory Status in the EU

Sincalide holds a complex regulatory position in Europe. The compound is a cholecystokinin (CCK) analogue—a 4-amino acid peptide that mimics the natural hormone responsible for gallbladder contraction—but it has never received marketing authorisation from the EMA. This is the key legal fact that shapes its availability across all EU member states.

Unlike compounds such as Abaloparatide, which underwent the full European centralised procedure and gained EMA approval, sincalide was developed and approved primarily for the North American market. The EMA has no record of a Marketing Authorisation Application (MAA) for sincalide in the public domain, meaning pharmaceutical companies have not pursued formal European registration.

Current Approval Status Across Key Markets

Sincalide's regulatory footprint is genuinely asymmetrical:

United States: FDA-approved since 1982 (original approval as Kinevac®). The FDA maintains sincalide in its database of approved drugs, and it is available by prescription through licensed US pharmacies.

Canada: Health Canada approved sincalide (marketed as Sincalide Injection), confirming regulatory acceptance in the North American context.

European Union: No EMA marketing authorisation. The EMA's database of authorised medicines contains no sincalide entry. This means sincalide cannot be legally marketed, prescribed, or reimbursed as a pharmaceutical product in any EU member state.

Why Sincalide Was Never Approved in the EU

The absence of EU approval likely reflects several practical and commercial factors rather than safety concerns:

Timing: Sincalide was developed in the late 1970s and approved in the US in 1982, before the EMA's centralised procedure became the standard route for novel drugs. Companies at that time could pursue individual national approvals or skip Europe entirely if the market seemed less valuable.

Market Size: Sincalide is used for a specific diagnostic purpose—to stimulate gallbladder contraction during hepatobiliary scintigraphy. The European diagnostic imaging market may have seemed too small to justify the cost and complexity of securing EMA approval, especially as alternative diagnostic methods (ultrasound, magnetic resonance imaging) became more prevalent.

Regulatory Evolution: EMA standards have evolved significantly since the 1980s. Seeking approval today would require modern pharmacology data, risk–benefit analysis, and manufacturing compliance documentation—a substantial investment for an older, niche compound.

Enforcement and Legal Implications in EU Member States

Because sincalide lacks EMA authorisation, its status under EU pharmaceutical law is clear and legally binding across the bloc:

Marketing: Sincalide cannot be legally marketed, distributed, or advertised as a medicine in any EU member state, regardless of whether a doctor wishes to prescribe it.

Prescribing: While off-label use of approved medicines is permissible in some contexts within the EU, sincalide has no approved status in any form. Hospitals or clinics cannot legally obtain or use sincalide through normal pharmaceutical supply chains.

Cross-Border Importation: EU patients or practitioners cannot legally import sincalide from the US for personal or clinical use. The EMA's guidance on personal imports clarifies that non-authorised medicinal products fall outside the scope of legitimate personal importation exceptions.

Enforcement Responsibility: Individual EU member states' medicines regulators (equivalent to the EMA's role at the national level) are responsible for enforcing this prohibition. Unauthorised distribution of sincalide would likely be treated as a violation of Directive 2001/83/EC, the EU's primary pharmaceutical legislation.

Clinical Context: What Sincalide Does

To understand the regulatory gap, it helps to know sincalide's clinical role. Sincalide is a synthetic cholecystokinin (CCK) analogue used in nuclear medicine to assess gallbladder function during hepatobiliary imaging. It stimulates gallbladder contraction, allowing radiologists to visualize gallbladder ejection and detect dysfunction such as cystic duct obstruction or reduced ejection fraction.

Clinical trial data spanning decades—sincalide has been subject to 8 documented clinical trials in the modern era—supports its diagnostic utility. A landmark study published in the Journal of Nuclear Medicine demonstrated that sincalide-stimulated cholescintigraphy reliably identifies gallbladder dysfunction in symptomatic patients.

However, this clinical pedigree has not translated into European approval, likely because the compound was already established in North America before EMA centralisation became standard practice.

What This Means for EU Patients and Practitioners

For Patients: If you are in the EU and require hepatobiliary imaging to assess gallbladder function, your radiologist will use alternative diagnostic methods—most commonly ultrasound or magnetic resonance cholangiopancreatography (MRCP)—rather than sincalide-stimulated scintigraphy. These alternatives are widely available and clinically effective, though they may differ in sensitivity or specificity for certain pathologies.

For Healthcare Providers: EU hospitals cannot legally procure or use sincalide, even for research or compassionate use contexts. If a practitioner needs to perform sincalide-stimulated cholescintigraphy, they would need to pursue an unlicensed-medicine license from their national regulator—an extremely rare and administratively demanding process reserved for genuine medical necessity when no authorised alternative exists. In practice, this is unlikely to be approved for a diagnostic agent when non-pharmacological alternatives are available.

For Researchers: Academic researchers in EU institutions cannot use sincalide in clinical studies without explicit regulatory approval. The absence of EMA authorisation means sincalide cannot be supplied or administered to research subjects in the EU, which has effectively prevented EU-based clinical research on this compound.

Comparison to Other Peptide Compounds

The contrast with compounds like Abaloparatide, which secured EMA approval for osteoporosis, underscores sincalide's unique position. Abaloparatide (Eladynos®) underwent the full centralised EMA procedure and now benefits from EU-wide authorisation, pricing agreements, and reimbursement pathways. Sincalide, by contrast, remains orphaned from the European regulatory framework.

Other peptides such as Afamelanotide have successfully navigated the EMA process and are now legally available across the EU. This demonstrates that peptide therapeutics can achieve EU approval when companies invest in the regulatory pathway—sincalide's absence simply reflects a historical business decision rather than a blanket prohibition on peptide medicines in Europe.

Recent Regulatory Developments

As of the latest available information, there is no indication that sincalide's EU status has changed or will change imminently. The EMA's public register of medicines and the periodic updates to the EU's list of authorised medicinal products do not include sincalide. No pharmaceutical company has announced plans to seek EU approval for sincalide, which suggests the commercial case for such an investment remains unconvincing.

Summary: The Bottom Line for EU Patients and Practitioners

Sincalide is legally unavailable in the EU because it lacks EMA marketing authorisation. It is approved and used in the US and Canada, but European regulatory law explicitly prohibits its marketing and distribution. For clinical needs in hepatobiliary imaging, EU patients are directed toward approved diagnostic alternatives. Attempting to import sincalide for personal or clinical use violates EU pharmaceutical law and exposes individuals and institutions to regulatory action.

If you are a healthcare provider seeking sincalide-like diagnostic capabilities, consult your national medicines regulator about licensed alternatives. If you are a patient or researcher interested in sincalide for any purpose, the legal pathway forward in the EU is not available without a fundamental change in regulatory status—which currently appears unlikely.

Sincalide Legal Status in the EU: What You Need to Know